Loading
Montreal urologist who led the zoledronic acid trials in prostate cancer bone metastases and was lead author of ARANOTE, which established darolutamide plus hormone therapy for metastatic hormone-sensitive disease.
Fred Saad is chief of urology at the Centre hospitalier de l'Université de Montréal and a leading investigator in advanced prostate cancer. He led the trials that established zoledronic acid for bone metastases from castration-resistant prostate cancer and was first author of the 2024 Journal of Clinical Oncology report of ARANOTE, in which darolutamide plus androgen deprivation therapy improved radiographic progression-free survival in metastatic hormone-sensitive prostate cancer.
| Title | Journal | Year |
|---|---|---|
| ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer | New England Journal of Medicine | 2022 |
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.